CTII's cell therapy for diabetes
Noteworthy
CTII's cell therapy for diabetes
CytoTherapeutics Inc. was to announce today that it has begun Phase I trials of polymer-encapsulated islet cells that will be implanted in patients with Type I insulin-dependent diabetes and Type II diabetes, as well as in healthy volunteers.
The study is being conducted under an investigator-sponsored IND and CTII anticipates announcing results at a scientific forum at the end of the year.
The polymer membrane surrounding the